Last reviewed 01/2018
- angiotensinogen converting enzyme, resulting in reduced vasoconstriction and renin activation
- neutral endopeptidas,e resulting in elevated vasodilatory peptide concentrations
Omapatrilat was compared to lisinopril in 573 patients with NYHA grade II-IV heart failure. The patients had all required ACE inhibitor therapy prior to the trial.
Target doses were:
- 40 mg omapatrilat per day
- 20 mg lisinopril per day
Follow-up was 24 weeks.
The primary endpoint was exercise tolerance measured by a treadmill test at 12 weeks. Secondary endpoints included death, admission or discontinuation of treatment because of worsening heart failure.
- (1) Rouleau, JL, Pfeffer , MA. et al. (2000). Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet, 356, 615-20.